echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Xalreto and Eylea patent protection expired Bayer Pharmaceuticals revenue gap

    Xalreto and Eylea patent protection expired Bayer Pharmaceuticals revenue gap

    • Last Update: 2021-01-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At present, Bayer's pharmaceutical business is most concerned about its two best-selling products, blood thinner Xalreto and ophthalmology drug Eylea is about to face the risk of patent protection expiring.
    patent break for the two heavy-duty drugs will lead to an revenue gap for Bayer, the head of Bayer's pharmaceutical business said, and the company's existing production line projects will not be able to fill the revenue decline for years to come.
    revenue totaled $8 billion in 2019 after sales at Xarelto and Eylea grew by more than 10 percent.
    The head of Bayer's pharmaceutical business, Stefan Oelrich, told reporters on Wednesday that it was "mathematically impossible" for his new drug to receive revenue growth to compensate for the drop in revenue caused by the loss of patent protection, the Financial Times reported.
    no pharmaceutical company in the world can fill such a huge loss of revenue in a short period of time, " says Mr Oelrich.
    2020, Xarelto and Eylea lost key active ingredient patents in the Chinese market, and patent protections in other countries and regions are soon facing expiration.
    , however, as Oelrich said at the recent annual JP Morgan Health Care Conference. As Morgan Healthcare Conference points out, Bayer does have several potential heavy-bomb drugs that are expected to compensate for some of Xarelto and Eylea's lost revenue.
    include Nubeqa, a new drug for prostate cancer, which was approved by the FDA in July 2020 to treat patients with non-metastatic desopathic prostate cancer (nmCRPC).
    Last July, Bayer also announced that its Finerenone had become the first nonsteroidal selective salt corticosteroid inhibitor antagonist to be shown to reduce the risk of kidney and cardiovascular events in patients with type 2 diabetes (T2D) associated with chronic kidney disease (CKD).
    phase III FIDELIO-DKD trial, the combined application of finderenone reduced the risk of compound primary endpoints of CKD progression, kidney failure, and kidney death.
    Bayer's other promising drug, Vericiguat, is an oral, daily, first-of-its-kind soluble bird nucleotide cyclic enzyme (sGC) stimulant for the treatment of heart failure and is currently under FDA priority review.
    addition, Bayer last August bought KaNDy Therapeutics, a new non-hormonal oral therapy that improves menopausal symptoms, for $425 million in advance.
    NT-814 is a pioneering, non-hormonal, daily oral neurostitide-1,3-subject (NK1R/NK3R) antagonist and is expected to enter Phase III clinical trials in 2021.
    approval, analysts predict that NT-814's global sales peak could exceed 1 billion euros.
    in ceo Werner Baumann's restructuring plan, Bayer sees the use of resources for external research and development investments as part of the company's development strategy.
    in 2020 alone, Bayer Pharmaceuticals has reached more than 20 deals covering equity investments, licensing agreements and direct acquisitions.
    addition to KaNDy, Bayer last year bought Asklepios Bio Pharmaceutical, a pioneer in gene therapy, for as much as $4 billion.
    19, Bayer acquired BlueRock Therapeutics, which specializes in developing engineered cell therapies in neurology, cardiology and immunology using its proprietary induced pluripotent stem cell (iPSC) platform.
    , Oelrich told JP Morgan's annual meeting that Bayer still has the ability to make more deals in the future, but not exactly on the scale of last year's deal, as the decision depends largely on whether it is suited to Bayer's strategic direction.
    Oelrich said Bayer would "prioritize the impact and growth of its pharmaceutical business" in terms of capital allocation.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.